Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Ye L, Liu GX, Yang DL, Zeng FJ, Liu J, Yao HB, Nong JL, Liu SP, Peng N, Li WF, Wu PS, Qin C, Su Z, Ou JJ, Dong XF, Yan YH, Zhong TM, Wu MS, Chen YZ, Wang GD, Li MJ, Wang XY, Yang FQ, Chen SC, Yang YY, Chen K, Lai YC, Pang QQ, Liang XM, Mao XS, Liang YR, Li FX, Shi H, Li RJ, Xiang BD, Ma L, Zhong JH, Yu YQ, GUIDANCE investigators

Open source

DOI: 10.1159/000552409
Published: 2026 May 6
Container: Liver cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000552409,
  title = {Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.},
  author = {Ye L and Liu GX and Yang DL and Zeng FJ and Liu J and Yao HB and Nong JL and Liu SP and Peng N and Li WF and Wu PS and Qin C and Su Z and Ou JJ and Dong XF and Yan YH and Zhong TM and Wu MS and Chen YZ and Wang GD and Li MJ and Wang XY and Yang FQ and Chen SC and Yang YY and Chen K and Lai YC and Pang QQ and Liang XM and Mao XS and Liang YR and Li FX and Shi H and Li RJ and Xiang BD and Ma L and Zhong JH and Yu YQ and GUIDANCE investigators},
  year = {2026},
  journal = {Liver cancer},
  doi = {10.1159/000552409},
  url = {https://doi.org/10.1159/000552409}
}

RIS

TY  - JOUR
TI  - Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.
AU  - Ye L
AU  - Liu GX
AU  - Yang DL
AU  - Zeng FJ
AU  - Liu J
AU  - Yao HB
AU  - Nong JL
AU  - Liu SP
AU  - Peng N
AU  - Li WF
AU  - Wu PS
AU  - Qin C
AU  - Su Z
AU  - Ou JJ
AU  - Dong XF
AU  - Yan YH
AU  - Zhong TM
AU  - Wu MS
AU  - Chen YZ
AU  - Wang GD
AU  - Li MJ
AU  - Wang XY
AU  - Yang FQ
AU  - Chen SC
AU  - Yang YY
AU  - Chen K
AU  - Lai YC
AU  - Pang QQ
AU  - Liang XM
AU  - Mao XS
AU  - Liang YR
AU  - Li FX
AU  - Shi H
AU  - Li RJ
AU  - Xiang BD
AU  - Ma L
AU  - Zhong JH
AU  - Yu YQ
AU  - GUIDANCE investigators
PY  - 2026
JO  - Liver cancer
DO  - 10.1159/000552409
UR  - https://doi.org/10.1159/000552409
ER  -

APA

L, Y., GX, L., DL, Y., FJ, Z., J, L., HB, Y., JL, N., SP, L., N, P., WF, L., PS, W., C, Q., Z, S., JJ, O., XF, D., YH, Y., TM, Z., MS, W., YZ, C., GD, W., MJ, L., XY, W., FQ, Y., SC, C., YY, Y., K, C., YC, L., QQ, P., XM, L., XS, M., YR, L., FX, L., H, S., RJ, L., BD, X., L, M., JH, Z., YQ, Y., & investigators, G. (2026). Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.. Liver cancer. https://doi.org/10.1159/000552409

Source records

pubmed · retrieved 2026-09-26T03:15:02.774Z